Although dornase alpha (recombinant human DNase) can thin the viscid pulmonary secretions of cystic fibrosis (CF), clinical trials in groups of unselected patients have shown only modest average improvements in pulmonary function. The product is very expensive, so in conjunction with purchasers we designed selection criteria and a protocol for a 2-week trial to target CF individuals who might gain most benefit. Treatment was to be continued in those showing > 10% improvement in pulmonary function. Those who had a trial of dornase alpha were followed up for 2 years.
INTRODUCTION
The genetic defect in cystic fibrosis (CF) causes the production of abnormally sticky mucus. This is of particular importance in the respiratory tract, where stasis of viscid bronchial secretions encourages bacterial infection and, in the subsequent inflammatory reaction, disintegrating neutrophils release large amounts of DNA which further increases the tenacity of the sputum. Nearly all deaths in CF are attributable to respiratory failure, and strategies aimed at preserving pulmonary function in these patients include satisfactory sputum clearance1.
Enzymes that cleave human DNA (DNase) have been shown to reduce the viscosity of CF sputum2, thereby assisting its clearance. In the 1950s and 1960s studies with bovine DNase showed an improvement in sputum clearance in CF patients, but severe allergic reactions prevented the therapy from being widely accepted3'4.
Recombinant human DNAse (dornase alpha) became available for patient use in 1994. Drug company sponsored trials have shown that dornase liquefies CF sputum and improves spirometric indices in some patients with CF5-11.
However, the long-term effects are unknown and there is no evidence that it improves survival. Lately, an authoritative publication suggested that the case for prescribing dornase for CF patients was not proven12. Furthermore, it is very expensive (L2 3 per 2.5 mg vial, the recommended minimum daily dose).
Despite these reservations, when dornase became available for clinical use in the UK it was widely publicized and many patients asked for its prescription. Because most CF patients are collected into specialist clinics which take patients from many different National Health Service (NHS) purchasing authorities, the widespread use of dornase might cause severe funding difficulties. Thus in our region, on behalf of all our NHS purchasers, representatives of the adult and paediatric regional CF services met with the lead purchasing authority and their pharmaceutical advisors before dornase became available for prescription in general practice. The aim of this meeting was twofold first, to draw up guidelines which the clinicians would agree to adhere to; and, second, to estimate the number of patients who might require this drug so that purchasers could make allowances for it in their budgets.
Here we present the guidelines for dornase derived for adult CF patients, and experience during the first 2 years of their use.
PATIENTS AND METHODS Formulation of guidelines
Whilst drug company sponsored trials with dornase had demonstrated spirometric improvement in groups of patients given the drug, clinicians could not judge which patients within each group would be likely to obtain benefit. Thus, in drawing up guidelines for the use of dornase in our region we relied not only on published data but also on the experience of the local adult and paediatric clinicians involved in the care of CF patients. For adult CF patients, these empirical guidelines were divided into two parts the fulfilment of criteria to be eligible for a trial of dornase, and the degree of response that would allow the patient to remain on the product.
Qualifying criteria
In keeping with good clinical practice, only those patients who were compliant and on maximum medical treatment were considered suitable for a trial of this product. Because of its mode of action, patients should be chronic sputum producers; and, to target those with at least moderate disease, only patients who required intravenous antibiotics and had spirometry of <70% predicted were selected. A 2- week trial period was chosen because most of the spirometric improvement with dornase occurs within this time period of treatment8'10' 3. Thus, to qualify for a trial of dornase, the adult CF patient must fulfil the following criteria:
* Should wish to have a trial of dornase * Should be a chronic sputum producer * Should be compliant with maximum other therapy for their CF * Should have a forced expiration volume in 1 s (FEVI) or forced vital capacity (FVC) <70% predicted * Should have required at least two courses of intravenous antibiotics in the year preceding the trial * Should be in a stable clinical state.
Trial of dornase
Patients who fulfilled these criteria were given a trial of nebulized dornase 2.5 mg per day. All women of childbearing age had a negative pregnancy test and were taking adequate contraceptive precautions. No patient had had a change in antibiotics or been admitted to hospital within 14 days of the trial beginning, and all had a stable FEV1 and FVC. In every case, spirometry was measured by a skilled pulmonary function technician using a Vitalograph dry spirometer, the best of three attempts being taken as the measurement. After spirometry, the patient was started on nebulized dornase 2.5 mg once daily for 14 days in accordance with the manufacturer's instructions, the first dose being given in hospital.
Those with a 10% or greater improvement in spirometry at 14 days were deemed responders and were invited to continue dornase. (Patients with CF have a to 13%) than normal individuals14'15, so improvement of less than 10% may not reflect a true change in lung function.)
Those patients who showed less spirometric improvement were told they could have a repeat trial of dornase at any time in the future.
Follow-up
Patients were returned to routine follow-up, and any major changes in therapy or possible side-effects from dornase were noted. All patients had spirometry at 3, 6, 9, 12, 18, and 24 months in the outpatient clinic at the same time of day, and body mass index (BMI) was measured before the trial and at 12 and 24 months. The number of intravenous antibiotic courses administered was recorded for 1 year before the trial and for each subsequent completed year after the trial.
Funding
All our NHS purchasing authorities agreed to provide funds for dornase, so long as the prescribing clinicians adhered to the guidelines. Additionally, it was agreed that all dornase would be prescribed direct from hospital pharmacies. General practitioners would be asked not to prescribe it for individual patients, and the purchasers agreed to reimburse the CF clinics directly for any dornase used within these guidelines.
Statistical analysis
Pulmonary function was evaluated by calculation of percentage changes from baseline values recorded just before starting dornase. This was defined as: 
RESULTS

Responders
Of the 25 patients who had the 2-week trial of dornase, 17 were 'responders' (mean improvement in FEVl 37%, range 12-114; mean FVC change 27%, and remained on the treatment. 6 of these had died by 2 years and, by comparison with the remaining responders, these patients had less spirometric improvement after the initial trial of dornase (P<0.05) (Figure 1 ), but had similar initial spirometry (Table 1) and BMIs and requirement for intravenous antibiotics ( Table 2 ). In the surviving responders, BMIs and need for intravenous antibiotics remained unchanged at 2 years ( Non-responders 8 patients did not show an improvement in pulmonary function of at least 10% (mean FEV 1 change -3%, range -13 to 8; FVC mean -2%, -36 to 5) after 2 weeks of dornase and did not remain on the treatment. Their initial spirometry results were similar to those of the responder group but they had required further courses of intravenous antibiotics in the preceding year (P<0.02) ( Table 2) and were older (P<O.05) (Table 1 ). Furthermore, all these nonresponders were alive at 2 years with unchanged spirometry (Table 1) , BMIs, and intravenous antibiotic requirements ( Table 2) .
Side-effects
Of the non-responders, one had increased haemoptysis during the trial, another had a fall in FVC of 36% and required hospital admission and 2 had transient hoarseness.
None of the responder patients reported any side-effects.
DISCUSSION
Company-sponsored studies performed both in the UK and North America have shown that CF patients without severe respiratory disease (FVC>40% predicted) have an average FEV1 gain of about 13% in the first month after dornase were calculated from a new baseline obtained after the two week washout period, which was over 5% below the pretrial baselines. Thus, the real average improvement at 2 years may be much less than this calculated figure. Furthermore, in a large phase III study only 30% of patients given a trial of dornase had >10% improvement in FEV1 (compared with 15% of patients given placebo), and 6% had >10% decrease in FEV1 (14% placebo)8. In CF patients with severe pulmonary disease (FVC <40% predicted), no significant improvement in spirometry was seen at 6 months on dornase treatment10. The largest trials of dornase have also shown small and not clinically significant improvements in the rate of infective exacerbations and CF-related symptom scores. These trials also showed that adult CF patients (>17 years) had more infections and less improvement in spirometry than younger patients whilst taking dornase8. Also, no trial has shown any improvement in survival and there is thus little evidence to show that dornase has any long-term benefit for CF patients. Because of this, some reviewers say that the case for dornase is not proven12. Furthermore, this product costs about £7500 per patient per year for the lowest recommended daily dose: in the UK, this is a greater cost than the total yearly drug bill for an average CF patient.
Because of the cost of the drug and its lack of proven long-term efficacy, we were interested in targeting those patients who might have the greatest clinical benefit. When deciding the time period for the dornase trial, we were aware that the published data showed that most of the spirometric response to dornase occurs within the first few days of its use. The authors of a recent retrospective study of dornase use in 65 CF children suggested a 3-month trial period'7, but this period seems to have been chosen because patients were routinely reviewed at a tertiary centre only every 3-4 months. In those patients with data for 2-4 weeks' dornase use, improvement was similar to that demonstrated at 3 months. We believe that a 2 week trial period under the care of the supervising clinician allows patients to be conveniently assessed in their local outpatient setting. Although our definition of response (10% improvement in spirometry) was arbitrary, our data show that most patients undertaking a trial of dornase either improved much more than 10% or very little at all. The fact that non-responders were older than responders and had needed fewer courses of intravenous antibiotics in the preceding year may indicate that they had more 'fixed' and stable pulmonary disease. In keeping with this, they had no deterioration in spirometry over the 2 year period, despite published data suggesting that the average CF patient shows an 8% decline in spirometry over this time18'9. It is noteworthy that those patients in company-sponsored dornase trials who received placebo alone had no deterioration in spirometry over similar time periods. Furthermore, the nutritional state and requirement for intravenous antibiotics in our 'non-responder' patients also remained unchanged. The lack of deterioration in these patients suggests that they had not been disadvantaged by our trial protocol. Responders who completed 2 years had an initial average improvement of 45% in FEVI and 27% in FVC, which decreased to 31% and 16% respectively at 2 years. Even within this group, the range of change from baseline at 2 years was large (-24% to + 136%) indicating that only a proportion of these responders were still deriving benefit from dornase.
In keeping with the published data we found that most patients tolerated dornase well, although one nonresponder had a worrying fall in pulmonary function after the trial and another had increased haemoptysis probably due to thinning of bronchial secretions. We believe that dornase has a role in the management of lung disease in some CF patients. However, it is possible that at present large numbers of CF patients are consuming this expensive resource without benefit whilst others are deprived of it for financial reasons. In future, other expensive innovative therapies are likely to become available for selected patient groups such as those with CF, and we have shown how, by cooperation with purchasers, a rational prescribing policy can be developed. We had no difficulties in obtaining funding for dornase from the eight purchasing authorities representing this selected patient group. Furthermore, since general practitioners do not prescribe the dornase, purchasers are able to forecast the use of this product within their CF population and budget accordingly. We suggest that our criteria provide a robust model for selecting and obtaining finance for those adult CF patients who might benefit from dornase therapy.
